A. Ernest WhitonChief Financial OfficerZOLL Medical Corporation+1 (978) 421-9655
Diane EganZOLL Medical Corporation+1 (978) email@example.com
Monday, December 19, 2005 – CHELMSFORD, MASS.—ZOLL Medical Corporation (NASDAQ: ZOLL), a manufacturer of resuscitation devices and software solutions, announced today that Boston-based Teradyne, Inc. (NYSE: TER), a supplier of automatic test equipment and interconnection systems, has chosen ZOLL’s AED Plus™ automated external defibrillator (AED) for deployment in Teradyne facilities in 15 countries, effective immediately.In addition, Teradyne has chosen En-Pro, Inc. (formerly ZOLLMD), a company affiliated with ZOLL, to provide the design, implementation, and ongoing management of the company’s AED program. En-Pro will also train Teradyne employees at all sites to act as first responders in the event of an emergency. Teradyne’s worldwide deployment is one of the most comprehensive AED programs undertaken by a New England-based company. Teradyne expects to have all of the AEDs deployed by the end of December 2005.“Safeguarding the health and safety of our employees is of primary importance to us, and ensuring that we provide a work environment that can deal with emergencies is a key part of that,” said Loren Eaton, vice president of Human Resources at Teradyne. “We believe that this product offers the best protection possible against sudden cardiac arrest in the workplace.”New American Heart Association guidelines, released in November, recommend that AED programs should be implemented in public locations, such as businesses, where there is a relatively high likelihood of witnessed sudden cardiac arrest (SCA).“Teradyne joins a growing list of Fortune 1000 companies that see the value of not only implementing a global early defibrillation program, but also committing the resources to do so,” said Richard A. Packer, president and chief executive officer of ZOLL. “By deploying this technology worldwide, Teradyne is taking a leadership role that we hope more companies will follow.”When a victim collapses from SCA, rescuers do not know whether defibrillation or CPR is the appropriate therapy until an AED is attached and the victim’s heart is analyzed. About half of all victims who suddenly collapse initially require defibrillation. For other victims who may have non-shockable heart rhythms, the critical action for survival is effective CPR.The ZOLL AED Plus is the first and only AED that helps rescuers perform effective CPR because it allows them to see and hear how well they are performing the rate and depth of chest compressions during CPR. This real-time feedback mechanism makes the ZOLL AED Plus the only AED that can help assess and treat nearly every SCA victim, making it the only Full-Rescue AED available today.
Teradyne (NYSE: TER) is a leading supplier of Automatic Test Equipment. The company’s products deliver competitive advantage to the world's leading electronics companies. In 2004, Teradyne had sales of $1.8 billion, and currently employs about 4,100 people worldwide. For more information, visit www.teradyne.com. Teradyne® is a registered trademark of Teradyne, Inc. in the U.S. and other countries.
ZOLL Medical Corporation is committed to developing technologies that help advance the practice of resuscitation. With products for pacing, defibrillation, circulation, ventilation, and fluid resuscitation, ZOLL provides a comprehensive set of technologies that help clinicians, EMS professionals, and lay rescuers resuscitate sudden cardiac arrest or trauma victims. ZOLL also designs and markets software that automates the documentation and management of both clinical and non-clinical information.ZOLL markets and sells its products in more than 140 countries. The company has direct operations, distributor networks, and business partners throughout the U.S., Canada, Latin America, Europe, the Middle East, Asia, and Australia. For more information, visit www.zoll.com or call +1 (978) 421-9655.Certain statements contained in this press release regarding matters that are not historical facts are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, ZOLL’s ability to compete in the AED Public Access Defibrillation (PAD) business; changes in regulations affecting the healthcare industry; general economic conditions; and those other factors discussed in the section entitled “Risk Factors” in ZOLL’s Quarterly Report on Form 10-K, which was filed with the SEC on December 15, 2005.© 2005 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. AED Plus is a trademark, and ZOLL is a registered trademark of ZOLL Medical Corporation. All trademarks are property of their respective owners.